The Ledger
Medtronic paid 650 million dollars in cash to complete its acquisition of SPR Therapeutics, adding an implant-free nerve stimulator for chronic pain to what the company calls the broadest pain-therapy portfolio in the industry. The deal, announced July 16, 2026, brings SPR’s SPRINT Peripheral Nerve Stimulation System, a 60-day percutaneous treatment that requires no permanent implant, into Medtronic’s Neuromodulation Operating Unit within its Neuroscience Portfolio. In company-cited clinical results, 60 percent of patients achieved at least a 50 percent reduction in pain, with an average 76 percent reduction among responders and a 56 percent reduction across all patients treated. Medtronic said the acquisition targets the roughly 50 million US adults living with chronic pain with a non-opioid, non-surgical option, and expects the deal to be minimally dilutive to adjusted earnings per share in fiscal 2027 and neutral to accretive after that. Confidence: High. Source: Medtronic’s acquisition announcement, company newsroom.
IPG Photonics offered 300 million euros, on a cash-free, debt-free basis, plus up to 50 million euros in earnout payments, to acquire Lumibird Medical and merge IPG’s urology laser business with Lumibird’s ophthalmology laser line. Lumibird Medical reported 112.2 million euros in revenue and 24.1 million euros in EBITDA, a 21.5 percent margin, for the fiscal year ended December 31, 2025. IPG said the deal, funded entirely with cash on hand, adds an estimated 1 billion dollars to its addressable market and is expected to be accretive to gross margin, EBITDA and adjusted earnings per share; IPG expects the transaction to close in the fourth quarter of 2026, subject to customary closing conditions. Confidence: High on the terms; Medium on the earnout’s ultimate value, since it depends on 2026 to 2027 performance not yet reported. Source: IPG Photonics’ acquisition announcement, company newsroom.
Jasper Therapeutics agreed to merge with Kira Pharmaceuticals in an all-stock deal paired with a roughly 132 million dollar private placement, betting on complement-pathway drugs for immune disease alongside Jasper’s existing anti-KIT antibody pipeline. The private placement, expected to close July 20, 2026, sold about 4.7 million shares of preferred stock to investors including Columbia Threadneedle Investments, Balyasny Asset Management, Ikarian Capital and Mirador Therapeutics; on a fully diluted basis, Kira’s former holders will own about 49.86 percent of the combined company, new private-placement investors about 43.46 percent, and Jasper’s original holders about 6.68 percent. The combined company keeps trading on Nasdaq under Jasper’s existing ticker, JSPR. Confidence: High on the deal terms; Medium on ultimate commercial value, since Kira’s complement-pathway programs remain in earlier-stage development. Source: Jasper Therapeutics’ merger announcement, GlobeNewswire.
REGENXBIO priced an underwritten public offering of 10,003,889 shares at 9.00 dollars each, plus 1,111,111 pre-funded warrants, a day after the mere announcement of the roughly 100 million dollar stock sale sent its shares down as much as 15 percent on dilution fears. The gene-therapy developer’s July 16 announcement disclosed only that it intended to sell about 100 million dollars of common stock, with Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho as joint book-running managers and underwriters holding a 30-day option to buy up to 15 percent more shares; the offering priced July 17 and is expected to close July 20, 2026. Confidence: High on the priced terms; Low on how the company will deploy the proceeds, since REGENXBIO has not detailed specific use of funds. Sources: REGENXBIO’s offering announcement, PR Newswire, REGENXBIO’s pricing announcement, PR Newswire.
THE DEAL SHEET
| Target | Acquirer/Investor | Vertical | Value | Source |
|---|---|---|---|---|
| SPR Therapeutics, Inc. | Medtronic plc | Medtech, neuromodulation and pain management | $650 million cash | Medtronic’s acquisition announcement, company newsroom |
| Lumibird Medical | IPG Photonics Corporation | Medtech, ophthalmology and urology lasers | Up to 350 million euros (300 million euros plus up to 50 million euro earnout) | IPG Photonics’ acquisition announcement, company newsroom |
| Kira Pharmaceuticals | Jasper Therapeutics, Inc. (all-stock merger, plus $132 million private placement) | Biopharma, complement therapies for immune disease | All-stock merger plus approximately $132 million private placement | Jasper Therapeutics’ merger announcement, GlobeNewswire |
| Brookdale Galleria community, Houston | Brookdale Senior Living Inc. | Senior housing, independent and assisted living | $23.4 million cash | Brookdale’s acquisition announcement, PR Newswire |
| Alamar Senior Living, Wellington, Florida | Health Wave Partners | Senior housing, assisted living and memory care | Undisclosed | Health Wave Partners’ acquisition announcement, BusinessWire via Morningstar |
HCA Healthcare’s second-quarter earnings call is set for July 24. Molina reports July 22, Community Health Systems around July 22 to 23, Universal Health Services July 27, Centene around July 28, Humana and Privia Health both around July 29 to August 6, and Cigna July 30.